SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994.
The SVLS team manages five private venture capital funds with approximately $1.9 billion of capital under management. The firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco.
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing- 29 October, 2013
SV Life Sciences Advisers notes that Delenex Therapeutics closes CHF 7.3 (USD 8.0) Million Series A3 Financing. Delenex Therapeutics AG, a biotechnology company developing topical and local treatments for dermatologic diseases using its proprietary PENTRA bodies, today announced the closing of a CHF 7.3 (USD 8.0) Million Series A3 round.
Ophthotech- IPO - September, 2013
NEW YORK, Sep 24, 2013 (BUSINESS WIRE) -- Ophthotech Corporation today announced the pricing of its initial public offering of 7,600,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts.